Open this publication in new window or tab >>Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
Department of Psychiatry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; Institute for Mental Health, Belgrade, Serbia.
Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Biomedical Engineering and Health Systems, Medical Imaging.
Karolinska Experimental Research and Imaging Center, Karolinska University Hospital, Solna, Sweden.
Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Show others...
2023 (English)In: Neuropathology and Applied Neurobiology, ISSN 0305-1846, E-ISSN 1365-2990, Vol. 49, no 1, article id e12867Article in journal (Refereed) Published
Abstract [en]
Aims: CYP2C19 transgenic mouse expresses the human CYP2C19 gene in the liver and developing brain, and it exhibits altered neurodevelopment associated with impairments in emotionality and locomotion. Because the validation of new animal models is essential for the understanding of the aetiology and pathophysiology of movement disorders, the objective was to characterise motoric phenotype in CYP2C19 transgenic mice and to investigate its validity as a new animal model of ataxia. Methods: The rotarod, paw-print and beam-walking tests were utilised to characterise the motoric phenotype. The volumes of 20 brain regions in CYP2C19 transgenic and wild-type mice were quantified by 9.4T gadolinium-enhanced post-mortem structural neuroimaging. Antioxidative enzymatic activity was quantified biochemically. Dopaminergic alterations were characterised by chromatographic quantification of concentrations of dopamine and its metabolites and by subsequent immunohistochemical analyses. The beam-walking test was repeated after the treatment with dopamine receptor antagonists ecopipam and raclopride. Results: CYP2C19 transgenic mice exhibit abnormal, unilateral ataxia-like gait, clasping reflex and 5.6-fold more paw-slips in the beam-walking test; the motoric phenotype was more pronounced in youth. Transgenic mice exhibited a profound reduction of 12% in cerebellar volume and a moderate reduction of 4% in hippocampal volume; both regions exhibited an increased antioxidative enzyme activity. CYP2C19 mice were hyperdopaminergic; however, the motoric impairment was not ameliorated by dopamine receptor antagonists, and there was no alteration in the number of midbrain dopaminergic neurons in CYP2C19 mice. Conclusions: Humanised CYP2C19 transgenic mice exhibit altered gait and functional motoric impairments; this phenotype is likely caused by an aberrant cerebellar development.
Place, publisher, year, edition, pages
Wiley, 2023
Keywords
animal models, cerebellar ataxia, cerebellum, cytochrome P-450 Cyp2c19, movement disorders, neuroimaging, transgenic mice
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:kth:diva-331168 (URN)10.1111/nan.12867 (DOI)001097583300003 ()36536486 (PubMedID)2-s2.0-85149216463 (Scopus ID)
Note
QC 20231204
2023-07-062023-07-062025-12-05Bibliographically approved